These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

199 related items for PubMed ID: 21679999

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Prostate Specific Antigen Testing after Radical Prostatectomy-Can We Stop at 20 Years?
    Ludwig WW, Feng Z, Trock BJ, Humphreys E, Walsh PC.
    J Urol; 2018 Jan; 199(1):114-119. PubMed ID: 28818527
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Prostate-specific antigen level, stage or Gleason score: which is best for predicting outcomes after radical prostatectomy, and does it vary by the outcome being measured? Results from Shared Equal Access Regional Cancer Hospital database.
    Mithal P, Howard LE, Aronson WJ, Kane CJ, Cooperberg MR, Terris MK, Amling CL, Freedland SJ.
    Int J Urol; 2015 Apr; 22(4):362-6. PubMed ID: 25728968
    [Abstract] [Full Text] [Related]

  • 6. Biochemical (prostate specific antigen) recurrence probability following radical prostatectomy for clinically localized prostate cancer.
    Han M, Partin AW, Zahurak M, Piantadosi S, Epstein JI, Walsh PC.
    J Urol; 2003 Feb; 169(2):517-23. PubMed ID: 12544300
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Lifelong yearly prostate specific antigen surveillance is not necessary for low risk prostate cancer treated with radical prostatectomy.
    Tollefson MK, Blute ML, Rangel LJ, Karnes RJ, Frank I.
    J Urol; 2010 Sep; 184(3):925-9. PubMed ID: 20643452
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Long-term outcome following radical prostatectomy in men with clinical stage T3 prostate cancer.
    Carver BS, Bianco FJ, Scardino PT, Eastham JA.
    J Urol; 2006 Aug; 176(2):564-8. PubMed ID: 16813890
    [Abstract] [Full Text] [Related]

  • 12. Time to prostate specific antigen recurrence after radical prostatectomy and risk of prostate cancer specific mortality.
    Freedland SJ, Humphreys EB, Mangold LA, Eisenberger M, Partin AW.
    J Urol; 2006 Oct; 176(4 Pt 1):1404-8. PubMed ID: 16952644
    [Abstract] [Full Text] [Related]

  • 13. Salvage radiotherapy for isolated prostate specific antigen increase after radical prostatectomy: evaluation of prognostic factors and creation of a prognostic scoring system.
    Buskirk SJ, Pisansky TM, Schild SE, Macdonald OK, Wehle MJ, Kozelsky TF, Collie AC, Ferrigni RG, Myers RP, Prussak KA, Heckman MG, Crook JE, Parker AS, Igel TC.
    J Urol; 2006 Sep; 176(3):985-90. PubMed ID: 16890677
    [Abstract] [Full Text] [Related]

  • 14. Determining When to Stop Prostate Specific Antigen Monitoring after Radical Prostatectomy: the Role of Ultrasensitive Prostate Specific Antigen.
    Matsumoto K, Komatsuda A, Yanai Y, Niwa N, Kosaka T, Mizuno R, Kikuchi E, Miyajima A, Oya M.
    J Urol; 2017 Mar; 197(3 Pt 1):655-661. PubMed ID: 27590477
    [Abstract] [Full Text] [Related]

  • 15. PSA doubling time as a predictor of clinical progression after biochemical failure following radical prostatectomy for prostate cancer.
    Roberts SG, Blute ML, Bergstralh EJ, Slezak JM, Zincke H.
    Mayo Clin Proc; 2001 Jun; 76(6):576-81. PubMed ID: 11393495
    [Abstract] [Full Text] [Related]

  • 16. Predictors of biochemical recurrence after Retzius-sparing robot-assisted radical prostatectomy: Analysis of 359 cases with a median follow-up period of 26 months.
    Abdel Raheem A, Chang KD, Alenzi MJ, Ham WS, Han WK, Choi YD, Rha KH.
    Int J Urol; 2018 Dec; 25(12):1006-1014. PubMed ID: 30276864
    [Abstract] [Full Text] [Related]

  • 17. Interval to biochemical recurrence following radical prostatectomy does not affect survival in men with low-risk prostate cancer.
    Bolton DM, Ta A, Bagnato M, Muller D, Lawrentschuk NL, Severi G, Syme RR, Giles GG.
    World J Urol; 2014 Apr; 32(2):431-5. PubMed ID: 23824175
    [Abstract] [Full Text] [Related]

  • 18. Prostate specific antigen versus prostate specific antigen density as a prognosticator of pathological characteristics and biochemical recurrence following radical prostatectomy.
    Magheli A, Rais-Bahrami S, Trock BJ, Humphreys EB, Partin AW, Han M, Gonzalgo ML.
    J Urol; 2008 May; 179(5):1780-4; discussion 1784. PubMed ID: 18343439
    [Abstract] [Full Text] [Related]

  • 19. Predictive factors of biochemical recurrence after radical prostatectomy for high-risk prostate cancer.
    Murata Y, Tatsugami K, Yoshikawa M, Hamaguchi M, Yamada S, Hayakawa Y, Ueda K, Momosaki S, Sakamoto N.
    Int J Urol; 2018 Mar; 25(3):284-289. PubMed ID: 29315854
    [Abstract] [Full Text] [Related]

  • 20. The Impact of Downgrading from Biopsy Gleason 7 to Prostatectomy Gleason 6 on Biochemical Recurrence and Prostate Cancer Specific Mortality.
    Ham WS, Chalfin HJ, Feng Z, Trock BJ, Epstein JI, Cheung C, Humphreys E, Partin AW, Han M.
    J Urol; 2017 Apr; 197(4):1060-1067. PubMed ID: 27847296
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.